Johnson Janssen Carvykti News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Regulatory authorities worldwide are tightening their monitoring mechanisms and launching their own investigations after reports of secondary malignancies potentially linked to chimeric antigen receptor T cell therapies.

South koreaSouth koreanJohnson janssen carvyktiNovarti kymriahBristol myers squibb abecmaShriya dasJanine jollySasmitha sahuHealthcare products regulatory agencyUniversity of pennsylvaniaA european medicines agencyKorea ministry of foodPharmacovigilance risk assessment committeeCarl juneBristol myers squibbEuropean medicines agency